The Swiss company said on Wednesday, the Swiss company said on Wednesday that Berlin (Reuters) -ROCE has entered an exclusive cooperation and licensing agreement with the Danish pharmaceutical pharmaceutical company to participate in the development of Petrelintide as a obesity treatment drug.
Under the terms of the agreement, Zealand Pharma will receive cash payments of $ 1.65 billion, with the possibility of prominent payments of $ 5.3 billion based on the development of the third stage of experiences and sales.
Zealand is currently testing Petrentide in individuals with weight gain or obesity without type 2 diabetes in the middle of the stage.
Petrelintide belongs to a group of drugs known as long -acting amylane analog, which mimics a hormone called amylene that is excreted with insulin in response to the foodstuffs that are eaten.
Ziophaland and Roth will jointly market Petrentide in the United States and Europe, and the Swiss company will obtain exclusive marketing rights in the rest of the world.
Roche said Petrelintide’s profits and losses, as well as a mixture of a fixed dose with the CT-388 of Roche, will be shared on the basis of 50/50 in the United States and Europe.
The deal is expected to be closed in the second quarter.
(Written by Miranda Murray, edited by Rachel Moore)
Discover more from
Subscribe to get the latest posts sent to your email.
